CurrentBlue Cross Blue Shield - TennesseePolicy N/A

Cardiovascular Disease Risk Assessment

Defines coverage and limitations for laboratory and biomarker testing used to assess cardiovascular disease risk for Blue Cross Blue Shield - Tennessee members, primarily adults. Applies to reimbursement determinations for lipid panels, specific biomarkers, and cardiovascular risk panels.

Policy Summary

PayerBlue Cross Blue Shield - Tennessee

PolicyCardiovascular Disease Risk Assessment

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateJul 1, 2023

Next Review DateN/A

Key ActionVerify member benefits and document the clinical indication when ordering lipid panels or advanced biomarkers; prior authorization may be required per member benefits.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

7/1/2023policy adoption date

Every 4-6 yearsroutine lipid interval

Annualincreased risk interval

Does not meettests not covered

40-75 yrsage range targeted

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for Cardiovascular Risk Testing

Coverage context and limitations

Coverage context and limitations — Summary of situations where testing is and is not supported, and how guideline evidence informs coverage decisions.

ALL of the following

Covered when clinically indicated
- Traditional lipid panel (total cholesterol, HDL-C, LDL-C, triglycerides) meets coverage when used for routine risk assessment every 4–6 years for adults 18–79 and more frequently (eg, annually) for individuals at increased ASCVD risk or when monitoring lipid-lowering therapy (eg, baseline, 4–12 weeks after statin initiation/change, then annually).
  See ACC/AHA, USPSTF, ADA, IDSA guidance referenced below.
- Apolipoprotein B (ApoB) measurement meets coverage for select indications including hypertriglyceridemia, diabetes, obesity/metabolic syndrome, other dyslipidemias (eg, very low LDL-C), on lipid therapy, and to help diagnose familial dyslipidemias (eg, familial combined hyperlipidemia, dysbetalipoproteinemia).
  Aligned with ACC/AHA and lipid management guideline risk-enhancing factor language.
- Lipoprotein(a) (Lp(a)) measurement meets coverage in adults for defined situations: family history of premature ASCVD or elevated Lp(a); individuals with premature ASCVD (men <55, women <65), particularly without traditional risk factors; primary severe hypercholesterolemia (LDL-C ≥190 mg/dL) or suspected familial hypercholesterolemia; and to inform treatment decisions in very-high-risk patients (eg, consideration of PCSK9 inhibitors).
  Aligned with ESC/EAS, ACC/AHA, and specialist society recommendations.
- High-sensitivity C-reactive protein (hs-CRP) meets coverage when, after quantitative risk assessment (eg, Pooled Cohort Equations), a risk-based treatment decision remains uncertain and hs-CRP would inform shared decision-making. Routine population screening or monitoring response to therapy with hs-CRP does not meet coverage.
  Reflects ACC/AHA and USPSTF considerations.
Not covered routinely / insufficient evidence
- High-sensitivity cardiac troponin T (hs-cTnT) does not meet coverage for outpatient cardiovascular risk assessment and stratification.
- Homocysteine testing does not meet coverage for CVD risk assessment, screening, evaluation, or routine management due to lack of evidence that lowering levels reduces CVD risk.
- Novel or proprietary multi-biomarker cardiovascular risk panels, and many nonstandard biomarkers (eg, apo A1, apo E, LDL/HDL subclasses, cystatin C, fibrinogen, Lp-PLA2, long-chain omega-3 fatty acids, intermediate density lipoproteins) do not meet coverage as adjuncts to standard lipid testing because clinical utility and impact on management or outcomes are unproven or inconsistent.
- Routine or repeated measurement of Lp(a) as a serial monitoring biomarker is not supported; Lp(a) is typically measured once to refine risk or when specific clinical indications exist.
Adjunctive tests to refine risk (eg, coronary artery calcium [CAC], ankle-brachial index [ABI], carotid intima-media thickness [CIMT]) may be reasonable in select patients when traditional risk assessment leaves treatment decisions uncertain; CAC has the strongest evidence for reclassification but is not recommended routinely for all patients. Clinical judgment and guideline-based criteria should guide use of these tests.
See ACC/AHA, ASCP, USPSTF, ESC guidance; CAC most useful for intermediate-risk patients per multiple societies.

Operational considerations and limitations:

- Testing should be intended to influence clinical management; routine testing without an actionable plan may not meet coverage.

Documentation of indication and how results will guide therapy is recommended.

- Frequency of lipid testing should follow guideline-based intervals (eg, every 4–6 years for average-risk adults, more frequent for higher risk or when initiating/changing therapy).

Avoid routine lipid testing more frequently than recommended unless indicated (eg, therapy initiation or monitoring).

- For individuals with HIV on antiretroviral therapy, obtain baseline lipid profile prior to ART initiation, 1–3 months after starting/modifying ART, then every 6–12 months thereafter (meets coverage).

Reflects IDSA/HIV Medicine Association guidance.

- Proprietary panels and many advanced/laboratory-developed biomarker panels lack demonstrated impact on patient outcomes and are considered not meeting coverage criteria unless individual component tests are separately indicated and supported by guideline-based rationale.

References and supporting literature

References and supporting literature — Key guidelines, systematic reviews, and primary studies that informed the coverage position.

1. Pear son, G. J., et al. (2021). 2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia. Can J Cardiol. (See recommendations on Lp(a), ApoB, and lipid monitoring intervals.)

2. Goff, D. C., et al. (2014). ACC/AHA guideline on the assessment of cardiovascular risk; and Arnett et al. (2019) ACC/AHA prevention guidance. (Support use of Pooled Cohort Equations, selective use of hs-CRP, family history, ABI, CAC as risk enhancers or for reclassification.)

3. Grundy et al. (2019). 2018 AHA/ACC Multisociety Guideline on the Management of Blood Cholesterol. (Defines ApoB and Lp(a) thresholds considered risk-enhancing factors.)

4. Wilson et al. (2019). Scientific statement on Lp(a) clinical use. (Provides indications for Lp(a) measurement in adults and youth.)

5. Visseren et al. (2021). 2021 ESC Guidelines on cardiovascular disease prevention. (Notes limited incremental value of many circulating biomarkers and recommendations on routine testing intervals.)

Coding and Thresholds

Imaging and specialized biomarker testingmixed

affected codes

placeholder for advanced imaging and biomarker testing codes referenced in reimbursement considerations

Referenced tests/proceduresmixed

affected codes

Not specified in this excerpt; tests referenced include lipid panels, Lp(a), Apo B, CAC, hsCRP

Referenced laboratory/tests (no billing codes provided)mixed

N/A	Commercial test references (Quest Cardio IQ® 9p21 Genotype) mentioned; no CPT/HCPCS/ICD codes listed in this section.

inv-32: Persistently elevated triglycerides — threshold value

Persistently elevated triglycerides>=175 mg/dL

ContextListed by ACC/AHA as a risk-enhancing factor for ASCVD

Use-caseConsidered when individualizing prevention decisions after global risk estimation

inv-33: Elevated hs-CRP as risk-enhancing factor — threshold value

hs-CRP risk-enhancing threshold>=2.0 mg/L

Analytic notehs-CRP requires high-sensitivity assay to detect low-range values relevant for asymptomatic risk (<3 mg/L)

Provider Actions, Documentation, and Authorization

Documentation Required

Clinical indication verification

Verify that the requested test is covered for the individual member and that the clinical indication and documentation support medical necessity before ordering. Coverage is contingent on meeting the specific clinical indications listed in this policy (eg, lipid panel indications, Lp(a) indications, apoB indications, HIV/ART monitoring, familial dyslipidemia evaluation, statin initiation/monitoring).

Confirm member benefit coverage at time of request
Document clinical indication and how results will affect management or therapy decisions

Documentation Required

Justify advanced biomarker testing

Advanced or novel biomarker testing (eg, inflammatory markers beyond hs‑CRP, NT‑proBNP for HF prognosis, novel lipid/non‑lipid biomarkers) should be ordered only when there is documented clinical rationale explaining how the result will change management. Provide supporting guideline references or patient‑specific justification given limited established net clinical benefit and cost‑effectiveness for many advanced biomarkers.

State specific management decision(s) contingent on test result

Background and Rationale

Cardiovascular risk assessment integrates patient risk factors and laboratory testing to estimate future event probability; a lipid profile (total cholesterol, LDL‑C, HDL‑C, triglycerides) remains the primary blood test for CVD risk assessment, and quantitative 10‑year ASCVD risk estimation with a clinician‑patient discussion is the foundation for primary prevention decision making.

Definitions and Biomarker Descriptions

inv-88: Lipid panel — components of a simple lipid panel

Lipid panel componentsTotal cholesterol; LDL cholesterol; HDL cholesterol; Triglycerides

Optional/calculatedCertain labs may also report calculated ratios such as total/HDL cholesterol

ExclusionsApolipoproteins, particle number/size, and Lp(a) are not considered components of a simple lipid panel

inv-89: Apo B — definition and clinical meaning

DefinitionApolipoprotein B (Apo B) is the major protein in LDL and VLDL; Apo B-100 is the principal form per LDL particle

Clinical meaningApoB concentration reflects LDL particle number and has been associated with atherosclerosis; may be preferred when TG high or LDL-C very low

References, Guideline Sources, and Revision History

The referenced literature list excerpt does not state explicit coverage exclusions; it provides bibliographic citations supporting the policy's evidence base rather than adding new exclusion language.

2023-07-01policy_adoptionLatest

Policy adopted and became effective based on Avalon recommendation; reimbursement decisions follow the adopted Avalon recommendation.

Policy Summary

PayerBlue Cross Blue Shield - Tennessee

PolicyCardiovascular Disease Risk Assessment

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateJul 1, 2023

Next Review DateN/A

Key ActionVerify member benefits and document the clinical indication when ordering lipid panels or advanced biomarkers; prior authorization may be required per member benefits.

SourceLink

On This Page

6. Piepoli et al. (2016). 2016 European Guidelines on CVD prevention. (Recommend against routine biomarker screening for risk stratification; repeat risk assessment intervals.)

7. Thompson et al. (2020) and HIV Medicine Association updates. (Guidance on lipid testing frequency for persons with HIV receiving ART.)

8. USPSTF (2018). Risk assessment for cardiovascular disease with nontraditional risk factors — addresses insufficient evidence for routine use of many nontraditional biomarkers for risk screening.

9. Boekholdt et al. (2014); Trompet et al. (2018). (Evidence on statin benefit and the role of ApoB as a risk factor.)

10. Willeit et al. (2018); Antonopoulos et al. (2022). (Analyses of Lp(a) and inflammatory biomarkers' incremental prognostic value and caveats regarding net clinical benefit and cost-effectiveness.)

11. Rosenson R., et al. (2022). (Reviews on ApoB, Lp(a), and other lipid biomarkers and their clinical applicability.)

12. Additional supporting citations: Piepoli MF et al., 2016; Pearson et al., 2021; Visseren F.L.J. et al., 2021; Aberg et al., 2014; Garber et al., 2020; Januzzi et al., 2019; Mohler et al., 2008.

Guideline contextIncluded as a risk-enhancing factor to individualize clinician–patient risk discussions

inv-34: Elevated Lp(a) risk threshold — threshold value

Lp(a) risk-enhancing threshold>=50 mg/dL or >=125 nmol/L

Baseline/on-statins noteBaseline risk association begins around >=30 mg/dL; on-statin thresholds evaluated at >=50 mg/dL

Clinical indicationRelative indication: family history of premature ASCVD or to refine high-risk decisions

inv-35: Elevated apoB threshold — threshold value

ApoB risk-enhancing threshold>=130 mg/dL

Corresponding LDL-CLevel >=130 mg/dL corresponds approximately to LDL-C >=160 mg/dL

IndicationsConsider measurement with high triglycerides or dyslipidemia to refine risk assessment

inv-36: ABI abnormal — threshold value

Abnormal ABI threshold<0.9

Use-caseABI <0.9 considered a risk-enhancing finding to inform treatment decisions

ReferenceListed among ACC/AHA risk-enhancing factors

inv-37: Lp(a) risk thresholds — baseline and on-statin values

Lp(a) baseline threshold>=30 mg/dL (baseline association reported)

Lp(a) on-statin threshold>=50 mg/dL (on-statin association reported)

Study evidenceWilleit et al. showed HR increases at these baseline and on‑statin thresholds

inv-38: NT-proBNP prognostic threshold — value associated with outcomes

NT-proBNP prognostic threshold<=1,000 pg/ml

Clinical implicationNT-proBNP <=1,000 pg/mL during guideline-directed therapy associated with better outcomes in HFrEF

Source studyJanuzzi et al., GUIDE-IT trial analysis

inv-39: hs-CRP detection range — analytic detection details

hs-CRP analytic detection rangeDetects down to ~0.3 mg/L (uses high-sensitivity assays) up to levels >3 mg/L; traditional CRP assays limit ~3-5 mg/L

Implicationhs-CRP is required to assess low-grade inflammation in asymptomatic individuals

Documentation guidanceWhen ordering, document assay type (hs-CRP vs traditional CRP) and measured value

inv-40: hs-CRP — guideline threshold

Guideline hs-CRP cutoff>=2.0 mg/L

RoleConsidered a risk-enhancing factor to individualize prevention decisions

Assay requirementRequires high-sensitivity assay to detect this low-range elevation

inv-41: Lp(a) — guideline threshold

Guideline Lp(a) threshold>=50 mg/dL or >=125 nmol/L

Guideline recommendationLp(a) may be measured to refine risk in specified scenarios (family history, premature ASCVD, suspected FH)

Very high level note>180 mg/dL (>430 nmol/L) identified by ESC as equivalent lifetime risk to heterozygous FH

inv-42: ApoB — guideline threshold

Guideline ApoB threshold>=130 mg/dL

Clinical useApoB recommended in people with high TG, diabetes, obesity, very low LDL-C; may be used as alternative to LDL-C

Corresponding LDL-CApoB >=130 mg/dL corresponds to LDL-C >=160 mg/dL

inv-43: hs-troponin I (example quartile cutoff) — study cutoff

Example hs‑troponin I study cutoff (highest quartile)>=5.2 ng/L

Study contextFord et al. reported HR 2.3 for highest vs lowest quartile (>=5.2 vs <=3.1 ng/L) relating troponin to CHD risk

Clinical implicationElevated high-sensitivity troponin may stratify future CVD risk beyond traditional factors

inv-44: EPA/AA ratio — associated threshold

EPA/AA ratio associated threshold>0.75

Clinical findingEPA/AA >0.75 associated with fewer major coronary events in one Japanese population study

ConsiderationSubstantial individual variability; may guide personalized omega-3 recommendations

inv-45: Triglycerides (hypertriglyceridemia) — threshold

Hypertriglyceridemia threshold>=175 mg/dL

Clinical rolePersistently elevated triglycerides considered a risk-enhancing factor; use non-HDL-C or apoB if TG >1.5 mM

Severity noteSevere hypertriglyceridemia defined separately as TG >=500 mg/dL

inv-46: Lp(a) very high threshold — values associated with FH-level risk

Very high Lp(a) threshold>180 mg/dL (>430 nmol/L)

Clinical significanceESC/EAS: such levels may confer lifetime ASCVD risk similar to heterozygous familial hypercholesterolemia

RecommendationConsider measurement at least once to identify very high inherited levels

inv-47: LDL-C familial hypercholesterolemia threshold — adult and pediatric values

LDL-C threshold for familial hypercholesterolemia (adults)>=190 mg/dL

Pediatric threshold>=160 mg/dL (children)

Reporting recommendationReport LDL-C >=190 mg/dL as possible FH (Strength I, Evidence B-NR)

inv-48: Severe hypertriglyceridemia — threshold

Severe hypertriglyceridemia thresholdTriglycerides >=500 mg/dL

Reporting actionRecommend reporting as severe hypertriglyceridemia (Strength I)

Clinical concernAssociated with pancreatitis risk and requires specific management

inv-49: Triglyceride threshold — alternate unit threshold

Alternate triglyceride unit threshold> 1.5 mM (~133 mg/dL)

GuidanceWhen TG >1.5 mM, prefer non-HDL-C or apoB for risk assessment in intermediate/high-risk individuals (CCS guidance)

Unit note1.5 mM corresponds approximately to 133 mg/dL; policy cites >1.5 mM as a threshold to change parameter preference

inv-50: Obesity definition for screening — BMI threshold

Obesity definition for screeningBMI >= 30 kg/m2

ContextListed as a risk condition prompting more frequent lipid assessment and consideration of ApoB/non-HDL-C

Population noteApplies in guidance for special-population screening (eg, endocrine/HIV considerations)

inv-51: High-Sensitivity Troponin-T/I — no numeric thresholds provided

Numeric thresholds not providedNo specific numeric cutoffs for high-sensitivity troponin-T/I are provided in policy guidance section

Study referencesMultiple studies cited that evaluate hs-cTnT/I associations with outcomes (e.g., Tang et al., Suthahar et al., Ford et al.)

ImplicationThough no policy numeric threshold, elevated hs‑cTn levels correlate with higher CVD risk and are discussed in cited literature

Cite guideline or literature supporting use when available (eg, ACC/AHA, ESC/EAS, NLA)

Prior Authorization

Proprietary multi‑marker panels may require prior authorization

Proprietary multi‑marker cardiovascular panels (commercial risk panels or algorithmic scores) lack established clinical utility and may require prior authorization. These panels often report multiple analytes or a single proprietary score; plan may deny panels that do not demonstrate impact on clinical management.

Examples include Genova CV Health Plus™, Cleveland HeartLab CVD profiles, Singulex panels, WellnessFX packages
Provide prior authorization or clinical justification if ordering a proprietary panel; list individual component tests and rationale

Documentation Required

Follow government coverage rules; note LDT status

Follow applicable government coverage rules where they exist. If federal or state policy (eg, LCD/NCD for Medicare, state Medicaid rules) conflicts with this policy, the government policy prevails. Also note that many laboratory‑developed tests (LDTs) are CLIA high‑complexity tests not FDA‑cleared; document LDT status when relevant.

Check LCD/NCD or state Medicaid coverage for members subject to those programs
If test is an LDT, document that it is an LDT and CLIA complexity level in the medical record

Prior Authorization

Prior authorization — not specified (verify per plan)

No specific universal prior authorization requirement is specified in this policy for most individual tests; however, some proprietary panels or commercial tests may be subject to plan prior authorization or review. Always verify plan‑specific prior authorization rules.

Verify plan-specific prior authorization portals or medical policy pages
If unclear, obtain predetermination or prior authorization before testing

Billing Rule

Prior authorization and reimbursement note

Reimbursement follows the plan's adopted guidance; this policy adopted the Avalon recommendation effective 7/1/2023. Note that specific reimbursement and coding decisions may reflect referenced guideline recommendations and adopted evidence reviews.

Effective date: 7/1/2023 — adopted Avalon policy recommendation
Reimbursement and coding follow payer rules and referenced guideline evidence

Denial Risk

Denial for specified tests

The following tests and panels DO NOT MEET COVERAGE CRITERIA and are subject to denial: hs‑cTnT for outpatient CVD risk stratification, homocysteine for CVD risk assessment, many novel lipid and non‑lipid biomarkers as adjuncts to LDL‑C, cardiovascular risk panels, intermediate density lipoprotein measurement, Lp‑PLA2, and long‑chain omega‑3 fatty acid RBC measurement.

High‑sensitivity cardiac troponin T (hs‑cTnT) — outpatient risk assessment: NOT COVERED
Homocysteine for CVD risk assessment: NOT COVERED
Proprietary cardiovascular risk panels: NOT COVERED
Lp‑PLA2, serum intermediate density lipoprotein, omega‑3 RBC: NOT COVERED

Documentation Required

Use of proprietary multi‑marker cardiovascular panels

Use of proprietary multi‑marker cardiovascular panels is discouraged unless there is clear evidence that panel results will change patient management; when ordered, list each component analyte and provide rationale. Proprietary algorithms that yield a single score are of limited demonstrated utility.

Provide breakdown of panel components and clinical intent
Indicate alternative standard testing already performed (eg, standard lipid panel, apoB, Lp(a) when indicated)

Note

No authorization or denial criteria are provided for some tests

This policy section does not provide exhaustive real‑time authorization or denial criteria for every vendor test; absence of explicit authorization/denial language here does not imply automatic coverage. Operational authorization triggers and plan‑specific requirements may exist elsewhere.

No authorization or denial criteria are listed for some vendor/tests in the references
Confirm coverage via payer medical policy lookup or prior authorization if required

Step Therapy

Step therapy — none specified in this section

There are no explicit step‑therapy requirements described within this section. If step therapy applies for a therapy related to testing (eg, requirements for escalating lipid‑lowering therapy before PCSK9 access), such rules will be found in the drug or benefit policy.

No step therapy instructions provided here — verify drug/medical policy for therapy step requirements

Documentation Required

Statin therapy response documentation

Document baseline and follow‑up statin therapy information when relevant: prior statin intensity, timing of therapy changes, laboratory monitoring intervals, and clinical response to therapy. Lipid panel monitoring guidance: up to every 4–12 weeks after statin initiation/change, then annually once stable.

Record prior statin dose/intensity and lipid response
Document dates of therapy initiation/changes and subsequent lipid measurements

Documentation Required

Biomarker assay and result documentation

Document assay type, method, and timing for biomarkers (eg, hs‑CRP assay type, NT‑proBNP, apoB, Lp[a]) and how results will be used. For Lp(a), indicate whether measurement is in mg/dL or nmol/L and if isoform‑insensitive assay methods were used when available.

Record assay methodology (eg, ELISA, ultracentrifugation, instrument platform) and laboratory performing the test
Specify units reported (mg/dL vs nmol/L for Lp(a)) and expected clinical thresholds

Documentation Required

Laboratory standardization

Ensure laboratory quality and standardization: prefer labs participating in CDC Lipids Standardization Program (LSP) or other recognized proficiency programs. Accurate measurement of lipid parameters and apolipoproteins improves clinical decision making.

Document lab certification/certificates (eg, CDC LSP participation) when available
Use CDC‑traceable methods for TC, TG, HDL‑C, LDL‑C, apoA‑I, apoB when possible

Documentation Required

Clinical documentation for risk assessment

For comprehensive risk assessment, document detailed clinical information: full cardiovascular history, family history of premature ASCVD, reproductive history in women, comorbid conditions (eg, diabetes, CKD, HIV), baseline and follow‑up labs, and which risk calculator was used (eg, Pooled Cohort Equations).

Note risk‑enhancing factors considered and how biomarker testing influenced shared decision‑making
Include baseline labs and timing of subsequent tests

Documentation Required

LDT/CLIA documentation

If a test is an LDT or high‑complexity CLIA test, document that status in the record (LDT designation, CLIA complexity) and be aware that LDTs are not FDA‑cleared though used clinically. This may affect interpretation and coverage determinations.

Record whether test is performed as an LDT and the performing lab's CLIA status
Include any available validation or performance data if relevant to prior authorization

Documentation Required

Guideline documentation sources

When citing clinical rationale for testing, reference authoritative guidelines and supporting literature (eg, ACC/AHA cholesterol guideline, ESC/EAS dyslipidemia guideline, AHA/ACC risk assessment statements, NLA scientific statements, ADA guidance).

Cite specific guideline sections that support testing indication (eg, Lp(a) or apoB guidance)
Attach guideline excerpts to prior authorization or chart documentation when applicable

Documentation Required

Documentation notes (vendor/test entries)

Vendor or test‑specific entries in the references may inform documentation for genetic or specialty testing but do not imply coverage. Include vendor/test details in documentation but do not rely on vendor marketing to justify medical necessity.

List vendor/test name, panel components, and supporting evidence in the medical record or authorization request
Do not substitute vendor claims for peer‑reviewed guideline evidence

Documentation Required

Supporting clinical references

This policy references multiple clinical guidelines and original studies as supporting clinical evidence. When ordering or justifying tests, include pertinent supporting references (eg, ACC/AHA 2018/2019 guidelines, ESC/EAS 2019/2021, National Lipid Association statements, CDC LSP documentation, selected meta‑analyses).

Attach or reference applicable guideline citations in authorization requests or chart notes
Use guideline thresholds (eg, Lp(a) ≥50 mg/dL or ≥125 nmol/L; hs‑CRP ≥2 mg/L) when relevant

Documentation Required

Lipid parameter preference

For lipid interpretation, prefer non‑HDL‑C or apoB when triglycerides >1.5 mM as the preferred lipid parameter for screening/targets. Repeat Lp(a) is generally not indicated; measure once to inform lifetime risk unless there is specific indication for repeat testing.

Use non‑HDL‑C or apoB as preferred parameter when TG >1.5 mM
Measure Lp(a) once in lifetime for risk stratification unless specific management rationale exists

Guideline noteApoB measurement is reasonable for initial evaluation and on therapy; >=130 mg/dL considered a risk-enhancing factor

inv-90: BNP / NT-proBNP — definition and clinical use

DefinitionBNP and NT‑proBNP are ventricular peptides released with increased cardiac pressure/volume

Clinical useEstablished diagnostic and prognostic markers in heart failure; NT‑proBNP <=1,000 pg/mL associated with better outcomes in HFrEF

LimitationsWide value ranges influenced by factors like obesity; BNP-guided strategies have mixed outcome evidence

inv-91: Lp(a) — definition and genetic determinants

DefinitionLipoprotein(a) is an LDL-like particle with atherogenic potential; serum levels largely genetically determined

Genetic determinantsLevels driven by apo(a) isoforms and polymorphisms; standard measurement challenges exist due to isoform variability

Clinical roleAssociated with modestly increased CAD risk around >=30–50 mg/dL; ESC recommends measuring once to identify very high inherited levels

inv-92: hs-CRP — assay characteristics and use

Assay characteristicshs-CRP assays detect CRP down to ~0.3 mg/L enabling assessment of low-grade inflammation

Clinical useUseful for cardiovascular risk assessment in asymptomatic individuals; traditional CRP assays detect ~3-5 mg/L and are less useful

DocumentationWhen ordering, document assay type (hs-CRP vs traditional CRP) and measured value for clinical interpretation

inv-93: hs-CRP — analytic detection detail (duplicate inventory entry)

Analytic detail (duplicate)High-sensitivity CRP assays detect down to ~0.3 mg/L; traditional CRP limit ~3-5 mg/L

Applicationhs-CRP used to quantify low-range inflammation relevant to ASCVD risk prediction

Overlap noteDuplicate inventory entry mirrors hs-CRP detection range and use

inv-94: Remnant cholesterol / IDL — definition

DefinitionRemnant cholesterol/IDL is the cholesterol content of triglyceride‑rich lipoproteins (VLDL and IDL fasting; plus chylomicron remnants non‑fasting)

Clinical relevanceElevated remnant cholesterol is associated with increased CVD risk; TG levels can estimate remnant cholesterol when advanced testing not available

Measurement noteOften inferred from TG in routine labs; advanced lipoprotein testing not routinely recommended for screening

inv-95: High-sensitivity troponin (hs-cTnI, hs-cTnT) — definition and relevance

DefinitionHigh-sensitivity cardiac troponin assays detect low-level cardiac injury (hs‑cTnI, hs‑cTnT)

RelevanceElevated hs‑cTn levels predict future CVD events and mortality and may improve risk stratification beyond traditional factors

Study notesMultiple cohort studies cited (Ford et al., Tang et al., Suthahar et al.) showing associations and sex differences in prognostic value

inv-96: FH — familial hypercholesterolemia definition

DefinitionFamilial hypercholesterolemia (FH) identified by very high LDL‑C and family history

Diagnostic thresholdsLDL‑C >=190 mg/dL in adults (report as possible FH); >=160 mg/dL in children

Clinical actionFlagging for FH prompts cascade screening and specialized management

inv-97: Very high Lp(a) — definition and clinical significance

Definition of very high Lp(a)>180 mg/dL (>430 nmol/L)

Clinical significanceESC: levels >180 mg/dL confer lifetime ASCVD risk similar to heterozygous FH

Measurement recommendationConsider measuring Lp(a) at least once in adult life to identify very high inherited levels

inv-98: metabolic risk — components of metabolic risk

ComponentsElevated blood pressure; increased waist circumference; elevated fasting triglycerides; low HDL‑C; elevated glycemia

UseDefined as 'metabolic risk' components relevant to risk assessment and therapy decisions

Clinical applicationPresence of metabolic risk factors may prompt more frequent lipid monitoring and tailored risk discussion

inv-99: Laboratory-developed test (LDT) — definition and regulatory context

DefinitionLaboratory‑developed test (LDT) is developed and performed in‑house and regulated by CMS under CLIA as high‑complexity; not FDA‑cleared/approved

Coverage implicationLDT status may affect coverage/prior authorization considerations and documentation requirements

DocumentationDocument LDT and CLIA high‑complexity status when relevant

inv-100: High-sensitivity cardiac troponin — study references and analytic notes

Study referencesMultiple studies (Ford et al. 2016; Tang et al. 2020; Suthahar et al. 2020) examine hs‑cTn associations with outcomes

Analytic notesHigh-sensitivity assays preferred; sex differences and age-related thresholds reported in literature

Policy stancePolicy cites evidence but does not set routine screening thresholds for hs‑troponins

inv-101: Natriuretic peptides (BNP/NT-proBNP) — definitions and references

DefinitionNatriuretic peptides (BNP/NT‑proBNP) are ventricular hormones elevated with increased cardiac pressure/volume

Clinical usesDiagnostic and prognostic markers in heart failure; NT‑proBNP thresholds have prognostic implications (<=1,000 pg/mL)

EvidenceGUIDE‑IT trial analysis and other studies cited supporting prognostic value

inv-102: 9p21 — genetic locus description and studies

9p21 locusGenetic locus on chromosome 9p21 associated with coronary artery disease risk; multiple studies evaluate its association

Research contextIncluded among genetic predictors and referenced systematic reviews/meta‑analyses

Clinical utilityGenetic information may provide incremental risk prediction but not routinely used for population screening in this policy

inv-103: Lipoprotein(a) / apoB — biomarkers discussed in cited literature

Biomarkers discussedLipoprotein(a) and ApoB are highlighted as important biomarkers with guideline support for selective measurement

LiteratureMultiple guideline and review sources cited discussing Lp(a)/ApoB utility in risk stratification

Clinical implicationThese biomarkers may refine risk in specific clinical contexts though overall incremental benefit is modest

inv-104: lipoprotein(a) — additional guideline/meta-analysis references

Additional referencesGuideline and meta‑analysis references support Lp(a) measurement in select situations and note analytic challenges

Policy takeawayMeasure Lp(a) at least once in adult life to identify very high inherited levels per ESC/CCS recommendations

Measurement caveatAssay methods and apo(a) isoform effects can affect accuracy; interpret in clinical context